海外の治験の状況「HPV」での検索結果
6件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Available
- A clinical study evaluating the safety, tolerability, and immune response to HPV vaccine given together with Bivalent RLP2086 vaccine in healthy subjects = 11 to < 18 years of age.
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years. MedDRA version: 14.1 Level: LLT Classification code 10004049 Term: Bacterial meningitis System Organ Class: 100000004862 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- United States
- 2013-05-23
Not Available
- The study is to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) vaccine (GSK580299) in healthy female subjects 10-25 years of age (inclusive).
- Healthy volunteers [For active immunisation of healthy adolescents and young adult females from the age of 10 to 25 years for the prevention of persistent infection, premalignant genital (cervical, vulvar and vaginal) lesions and cervical, vulvar and vaginal cancers (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic Human Papillomaviruses (HPV) types 16 and 18].;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Senegal, Tanzania, United Republic of
- 2017-09-15
Not Available
- Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) 580299 vaccine in healthy Chinese female subjects.
- Healthy volunteers;Therapeutic area: Diseases [C] - Cancer [C04]
- China
- 2015-06-11
Not Available
- Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine (GSK-580299) and Merck's Gardasil® vaccine when administered according to alternative 2-dose schedules in 9-14 years old females
- Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic human papillomaviruses (HPV). MedDRA version: 14.0 Level: LLT Classification code 10033723 Term: Papilloma viral infection NOS System Organ Class: 10021881 - Infections and infestations MedDRA version: 14.0 Level: LLT Classification code 10008229 Term: Cervical cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.0 Level: LLT Classification code 10056576 Term: Cervical intraepithelial neoplasia System Organ Class: 10038604 - Reproductive system and breast disorders ;Therapeutic area: Diseases [C] - Cancer [C04]
- Brazil, France, Hong Kong, Singapore, Sweden
- 2011-09-20
Not Available
- An Immunogenicity and Safety Study of GARDASIL™ in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years
- Prevention of HPV types 6, 11, 16 and 18 related cervical cancer, vulvar, vaginal pre-cancers, low-grade, pre-cancerous lesions, and genital warts in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years.;Therapeutic area: Diseases [C] - Cancer [C04]
- China
- 2015-04-02
Not Available
- Administration of 9valent vaccine against papillomavirus in HIV-positive women
- Immune responses to administration of 9valent vaccine against HPV in HIV-positive women MedDRA version: 20.0 Level: LLT Classification code 10020180 Term: HIV positive System Organ Class: 100000004848 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Belgium
- 2018-01-29
- 1
